放射治疗口咽癌患者最大标准化摄取值与局部控制的关系

IF 0.9 Q3 OTORHINOLARYNGOLOGY

Acta otorrinolaringologica espanola Pub Date : 2023-07-01 DOI:10.1016/j.otorri.2022.05.004

Anna Holgado , Xavier León , Miquel Quer , Valle Camacho , Alejando Fernández

{"title":"放射治疗口咽癌患者最大标准化摄取值与局部控制的关系","authors":"Anna Holgado , Xavier León , Miquel Quer , Valle Camacho , Alejando Fernández","doi":"10.1016/j.otorri.2022.05.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>To analyse the prognostic ability of the maximum standardised uptake value (SUV<sub>max</sub>) on local disease control in patients with oropharyngeal carcinoma treated with radiotherapy.</p></div><div><h3>Material and methods</h3><p>Retrospective study of 105 patients with oropharyngeal carcinomas treated with radiotherapy, including chemo- and bio-radiotherapy, and who had a PET-CT scan prior to the start of treatment.</p></div><div><h3>Result</h3><p>Patients with a SUV<sub>max</sub> value higher than 17.2 at the primary tumour site had a significantly higher risk of local recurrence. The 5-year local recurrence-free survival for patients with SUV<sub>max</sub> less than or equal to 17.2 (<em>n</em>  =34) it was 55.8% (95% CI: 36.0–75.6%) (<em>P</em>=.0001). This difference in local control was maintained regardless of patients’ HPV status. Specific survival was similarly lower for patients with a SUV greater than 17.2. The 5-year specific survival for patients with SUV<sub>max</sub> greater than 17.2 was 39.5% (95% CI: 20.6–58.3%), significantly shorter than that of patients with SUV<sub>max</sub> equal to or less than 17.2, which was 77.3% (95% CI: 66.9–87.6%) (<em>P</em>=.0001).</p></div><div><h3>Conclusions</h3><p>Patients with oropharyngeal carcinomas treated with radiotherapy with a SUV<sub>max</sub> greater than 17.2 at the level of the primary tumour site had a significantly higher risk of local recurrence.</p></div>","PeriodicalId":7019,"journal":{"name":"Acta otorrinolaringologica espanola","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Asociación entre el standarized uptake value (SUV) máximo y el control local en pacientes con carcinoma de orofaringe tratados con radioterapia\",\"authors\":\"Anna Holgado , Xavier León , Miquel Quer , Valle Camacho , Alejando Fernández\",\"doi\":\"10.1016/j.otorri.2022.05.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><p>To analyse the prognostic ability of the maximum standardised uptake value (SUV<sub>max</sub>) on local disease control in patients with oropharyngeal carcinoma treated with radiotherapy.</p></div><div><h3>Material and methods</h3><p>Retrospective study of 105 patients with oropharyngeal carcinomas treated with radiotherapy, including chemo- and bio-radiotherapy, and who had a PET-CT scan prior to the start of treatment.</p></div><div><h3>Result</h3><p>Patients with a SUV<sub>max</sub> value higher than 17.2 at the primary tumour site had a significantly higher risk of local recurrence. The 5-year local recurrence-free survival for patients with SUV<sub>max</sub> less than or equal to 17.2 (<em>n</em>  =34) it was 55.8% (95% CI: 36.0–75.6%) (<em>P</em>=.0001). This difference in local control was maintained regardless of patients’ HPV status. Specific survival was similarly lower for patients with a SUV greater than 17.2. The 5-year specific survival for patients with SUV<sub>max</sub> greater than 17.2 was 39.5% (95% CI: 20.6–58.3%), significantly shorter than that of patients with SUV<sub>max</sub> equal to or less than 17.2, which was 77.3% (95% CI: 66.9–87.6%) (<em>P</em>=.0001).</p></div><div><h3>Conclusions</h3><p>Patients with oropharyngeal carcinomas treated with radiotherapy with a SUV<sub>max</sub> greater than 17.2 at the level of the primary tumour site had a significantly higher risk of local recurrence.</p></div>\",\"PeriodicalId\":7019,\"journal\":{\"name\":\"Acta otorrinolaringologica espanola\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2023-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta otorrinolaringologica espanola\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0001651922000863\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"OTORHINOLARYNGOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta otorrinolaringologica espanola","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0001651922000863","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 1

摘要

目的分析最大标准化摄取值（SUVmax）对口咽癌放疗后局部疾病控制的预后能力。材料和方法对105名接受放疗（包括化疗和生物放疗）的口咽癌患者进行回顾性研究，这些患者在治疗开始前进行了PET-CT扫描。结果原发肿瘤部位SUVmax值高于17.2的患者局部复发风险明显较高。SUVmax小于或等于17.2（n=71）的患者的5年局部无复发生存率为86.5%（95%CI:78.2-94.7%），SUVmax大于17.2（n=34）的患者为55.8%（95%CI:36.0-75.6%）（P=0.001）。无论患者的HPV状况如何，局部控制的这种差异都得到了维持。SUV大于17.2的患者的比生存率同样较低。SUVmax大于17.2的患者的5年特异性生存率为39.5%（95%CI:20.6–58.3%），显著短于SUVmax等于或小于17.2的患者，其为77.3%（95%可信区间：66.9-87.6%）（P=0.001）。结论口咽癌患者接受放射治疗时，原发肿瘤部位SUVmax大于17.2，局部复发的风险显著较高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Asociación entre el standarized uptake value (SUV) máximo y el control local en pacientes con carcinoma de orofaringe tratados con radioterapia

Objective

To analyse the prognostic ability of the maximum standardised uptake value (SUV_max) on local disease control in patients with oropharyngeal carcinoma treated with radiotherapy.

Material and methods

Retrospective study of 105 patients with oropharyngeal carcinomas treated with radiotherapy, including chemo- and bio-radiotherapy, and who had a PET-CT scan prior to the start of treatment.

Result

Patients with a SUV_max value higher than 17.2 at the primary tumour site had a significantly higher risk of local recurrence. The 5-year local recurrence-free survival for patients with SUV_max less than or equal to 17.2 (n = 71) was 86.5% (95% CI: 78.2–94.7%), and for patients with SUV_max greater than 17.2 (n = 34) it was 55.8% (95% CI: 36.0–75.6%) (P=.0001). This difference in local control was maintained regardless of patients’ HPV status. Specific survival was similarly lower for patients with a SUV greater than 17.2. The 5-year specific survival for patients with SUV_max greater than 17.2 was 39.5% (95% CI: 20.6–58.3%), significantly shorter than that of patients with SUV_max equal to or less than 17.2, which was 77.3% (95% CI: 66.9–87.6%) (P=.0001).

Conclusions

Patients with oropharyngeal carcinomas treated with radiotherapy with a SUV_max greater than 17.2 at the level of the primary tumour site had a significantly higher risk of local recurrence.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Acta otorrinolaringologica espanola OTORHINOLARYNGOLOGY-

CiteScore

1.40

自引率

20.00%

发文量

审稿时长

44 days

期刊介绍： Es la revista más importante en español dedicada a la especialidad. Ofrece progresos científicos y técnicos tanto a nivel de originales como de casos clínicos. Además, es la Publicación Oficial de la Sociedad Española de Otorrinolaringología y Patología Cérvico-Facial y está presente en los más prestigiosos índices de referencia.